1 |
Coca SG,Singanamala S,Parikh CR.Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis[J].Kidney Int,2012,81 (5): 442-448.
|
2 |
Hoste EA,Bagshaw SM,Bellomo R,et al.Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study[J].Intensive Care Med,2015,41 (8): 1411-1423.
|
3 |
Al-Jaghbeer M,Dealmeida D,Bilderback A,et al.Clinical decision support for in-hospital AKI[J].J Am Soc Nephrol,2018,29 (2): 654-660.
|
4 |
Hoste EA,Clermont G,Kersten A,et al.RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis[J].Crit Care,2006,10 (3): R73.
|
5 |
Kurzhagen JT,Dellepiane S,Cantaluppi V,et al.AKI: an increasingly recognized risk factor for CKD development and progression [J].J Nephrol,2020,33(6): 1171-1187.
|
6 |
Wang Z,Zhang C.From AKI to CKD: maladaptive repair and the underlying mechanisms [J].Int J Mol Sci,2022,23 (18): 10880.
|
7 |
Teo SH,Endre ZH.Biomarkers in acute kidney injury (AKI)[J].Best Pract Res Clin Anaesthesiol,2017,31 (3): 331-344.
|
8 |
Yoon SY,Kim JS,Jeong KH,et al.Acute kidney injury: biomarker-guided diagnosis and management[J].Medicina (Kaunas),2022,58 (3): 340.
|
9 |
闫美辰,庞明敏,刘光凤,等.脓毒症相关急性肾损伤诊断和评估指标的研究进展[J/OL].中华危重症医学杂志(电子版),2023,16(5):414-421.
|
10 |
应利君,吕铁,李川吉,等.急性肾损伤患者启动早期肾替代疗法的相关指征及疗效研究[J/OL].中华危重症医学杂志(电子版),2021,14(1):45-48.
|
11 |
Parikh CR,Liu C,Mor MK,et al.Kidney biomarkers of injury and repair as predictors of contrast-associated AKI: a substudy of the PRESERVE trial [J].Am J Kidney Dis,2020,75 (2): 187-194.
|
12 |
Wen Y,Parikh CR.Current concepts and advances in biomarkers of acute kidney injury[J].Crit Rev Clin Lab Sci,2021,58 (5): 354-368.
|
13 |
Xiao Z,Huang Q,Yang Y,et al.Emerging early diagnostic methods for acute kidney injury [J].Theranostics,2022,12 (6): 2963-2986.
|
14 |
Husain-Syed F,Takeuchi T,Neyra JA,et al.Acute kidney injury in neurocritical care[J].Crit Care,2023,27 (1): 341.
|
15 |
Chaudhary K,Vaid A,Duffy A,et al.Utilization of deep learning for subphenotype identification in sepsisassociated acute kidney injury [J].Clin J Am Soc Nephrol,2020,15 (11): 1557-1565.
|
16 |
Wiersema R,Jukarainen S,Vaara ST,et al.Two subphenotypes of septic acute kidney injury are associated with different 90-day mortality and renal recovery[J].Crit Care,2020,24 (1): 150.
|
17 |
Pickkers P,Darmon M,Hoste E,et al.Acute kidney injury in the critically ill: an updated review on pathophysiology and management [J].Intensive Care Med,2021,47 (8): 835-850.
|
18 |
Gao Z,Mu DW,Guo L,et al.Etiological factors,prognostic assessment,and outcomes of patients with acute kidney injury and multiple organ dysfunction syndrome [J].Genet Mol Res,2014,13 (4): 8378-8384.
|
19 |
Chawla LS,Bellomo R,Bihorac A,et al.Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative(ADQI) 16 Workgroup [J].Nat Rev Nephrol,2017,13 (4): 241-257.
|
20 |
Hoste E,Bihorac A,Al-Khafaji A,et al.Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study [J].Intensive Care Med,2020,46 (5): 943-953.
|
21 |
Meng XM,Tang PM,Li J,et al.Macrophage phenotype in kidney injury and repair[J].Kidney Dis,2015,1 (2): 138-146.
|
22 |
Huen SC,Cantley LG.Macrophages in renal injury and repair[J].Annu Rev Physiol,2017 (79): 449-469.
|
23 |
Detheux M,Standker L,Vakili J,et al.Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties[J].J Exp Med,2000,192 (10): 1501-1508.
|
24 |
Rump L,Mattey DL,Kehoe O,et al.An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium[J].Cytokine,2017(97): 133-140.
|
25 |
Hannan NJ,Salamonsen LA.CX3CL1 and CCL14 regulate extracellular matrix and adhesion molecules in the trophoblast: potential roles in human embryo implantation[J].Biol Reprod,2008,79 (1): 58-65.
|
26 |
Bagshaw SM,Al-Khafaji A,Artigas A,et al.External validation of urinary C-C motif chemokine ligand 14(CCL14) for prediction of persistent acute kidney injury[J].Crit Care,2021,25 (1): 185.
|
27 |
Meersch M,Weiss R,Gerss J,et al.Predicting the development of renal replacement therapy indications by combining the furosemide stress test and chemokine(C-C motif) ligand 14 in a cohort of postsurgical patients[J].Crit Care Med,2023,51 (8): 1033-1042.
|
28 |
Massoth C,Küllmar M,Enders D,et al.Comparison of C-C motif chemokine ligand 14 with other biomarkers for adverse kidney events after cardiac surgery [J].J Thorac Cardiovasc Surg,2023,165 (1):199-207.e2.
|
29 |
Jiang W,Liao T,Yu J,et al.Predictability performance of urinary C-C motif chemokine ligand 14 and renal resistive index for persistent sepsis-associated acute kidney injury in ICU patients [J].Int Urol Nephrol,2023,55 (8): 1995-2003.
|
30 |
Peters-Sengers H,Van TSL.Association of urinary CCL14 with plasma protein biomarkers in critically ill sepsis patients with persistent acute kidney injury[J].NephrolDialTranspl,2023,38Suppl1:gfad063d_5569.
|